RxDoctor Payments Data

Daniel Barnes, MD

Family Medicine · Denver, NCNPI 1255372090

Payments from drug & device makers

$8,183in general payments, 2019–2025

Across 621 payments — averaging $13.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$706
  • Novo Nordisk$695
  • AstraZeneca$616
  • Pfizer$569
  • Amarin Pharma, Inc.$550
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$8,13799%
  • Education$461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,183 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$124,020
Medicare patients
246
Services billed
1,607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$119,604
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$59,251
EliquisApixaban63$55,120
MounjaroTirzepatide42$48,772
XareltoRivaroxaban44$43,318
JardianceEmpagliflozin30$42,028
FarxigaDapagliflozin Propanediol29$37,056
TrulicityDulaglutide22$35,157
LinzessLinaclotide28$28,222
RybelsusSemaglutide15$22,714
MyrbetriqMirabegron23$17,963
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$11,851
Repatha SureclickEvolocumab14$8,836
Lantus SolostarInsulin Glargine,hum.Rec.Anlog86$8,573
Tresiba Flextouch U-100Insulin Degludec17$6,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$695$142,318117 claims
Lilly USA, LLCMounjaro, Trulicity$706$83,92964 claims
GSKTrelegy Ellipta$381$59,25155 claims
PfizerEliquis$569$55,12063 claims
AstraZenecaFarxiga, Breztri Aerosphere$616$48,90644 claims
Johnson & JohnsonXarelto$303$43,31844 claims
Boehringer IngelheimJardiance$141$42,02830 claims
AbbVieLinzess, Synthroid$1,594$30,45255 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Denver

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →